多瑞医药
(301075)
| 流通市值：40.72亿 | | | 总市值：40.72亿 |
| 流通股本：8000.00万 | | | 总股本：8000.00万 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 136,998,003.2 | 106,572,557.63 | 49,443,387.5 | 240,628,115.62 |
| 营业收入 | 136,998,003.2 | 106,572,557.63 | 49,443,387.5 | 240,628,115.62 |
| 二、营业总成本 | 244,884,906.84 | 173,520,482.32 | 74,258,315.38 | 315,957,682.01 |
| 营业成本 | 130,655,304.23 | 102,232,391.47 | 41,173,602.76 | 138,565,119.17 |
| 税金及附加 | 2,671,086.28 | 1,881,375.33 | 1,004,871.11 | 2,120,122.6 |
| 销售费用 | 18,263,585.99 | 14,597,744.14 | 10,521,016.71 | 80,880,724.88 |
| 管理费用 | 39,544,732.33 | 26,455,515.13 | 11,790,524.92 | 54,164,144.37 |
| 研发费用 | 40,603,237.21 | 19,675,977.07 | 5,832,477.61 | 37,004,150.51 |
| 财务费用 | 13,146,960.8 | 8,677,479.18 | 3,935,822.27 | 3,223,420.48 |
| 其中:利息费用 | - | 9,881,874.75 | 4,201,164.89 | 7,900,196.15 |
| 其中:利息收入 | - | 1,247,486.27 | 280,793.1 | 4,740,791.72 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -56,833.33 | -56,833.33 | -54,425.55 | 541,833.33 |
| 加:投资收益 | 1,623,847.67 | 1,019,573.96 | 1,062,155.27 | 5,331,242.09 |
| 资产处置收益 | 9,561.89 | 9,561.89 | 9,561.89 | 43,526.49 |
| 资产减值损失(新) | -1,141,521.64 | 3,617,376.78 | -266,616.2 | -10,492,399 |
| 信用减值损失(新) | -9,699,817.7 | -1,176,342.66 | -1,053,138.23 | -7,318,184.14 |
| 其他收益 | 6,834,353.9 | 4,967,822.96 | 2,383,088.88 | 1,460,375.37 |
| 四、营业利润 | -110,317,312.85 | -58,566,765.09 | -22,734,301.82 | -85,763,172.25 |
| 加:营业外收入 | 38,217.61 | 10,248.61 | - | 580,164.91 |
| 减:营业外支出 | 872,488.97 | 166,311.4 | 113,355.07 | 588,342.12 |
| 五、利润总额 | -111,151,584.21 | -58,722,827.88 | -22,847,656.89 | -85,771,349.46 |
| 减:所得税费用 | 1,547,090.25 | 1,133,732.32 | -131,531.01 | -746,158.76 |
| 六、净利润 | -112,698,674.46 | -59,856,560.2 | -22,716,125.88 | -85,025,190.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -112,698,674.46 | -59,856,560.2 | -22,716,125.88 | -85,025,190.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -79,727,687.11 | -42,503,563.81 | -15,598,165.78 | -62,666,665.21 |
| 少数股东损益 | -32,970,987.35 | -17,352,996.39 | -7,117,960.1 | -22,358,525.49 |
| 扣除非经常损益后的净利润 | -84,948,541.88 | -45,517,269.77 | -17,008,092.26 | -66,454,473.65 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.01 | -0.54 | -0.2 | -0.79 |
| (二)稀释每股收益 | -1.01 | -0.54 | -0.2 | -0.79 |
| 八、其他综合收益 | - | - | - | 461,177.5 |
| 归属于母公司股东的其他综合收益 | - | - | - | 461,177.5 |
| 九、综合收益总额 | -112,698,674.46 | -59,856,560.2 | -22,716,125.88 | -84,564,013.2 |
| 归属于母公司股东的综合收益总额 | -79,727,687.11 | -42,503,563.81 | -15,598,165.78 | -62,205,487.71 |
| 归属于少数股东的综合收益总额 | -32,970,987.35 | -17,352,996.39 | -7,117,960.1 | -22,358,525.49 |
| 公告日期 | 2025-10-24 | 2025-08-27 | 2025-04-25 | 2025-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |